Indefinite Suspension of the De Minimis Exemption for Mail Shipments and New Postal Informal Entry Process
CBP indefinitely suspends the de minimis exemption for mail shipments and introduces a new postal informal entry process, requiring importers to file formal entries for low-value shipments, increasing compliance costs and delays.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) importing small quantities of samples, APIs, or finished drugs via mail. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective immediately upon publication (June 24, 2026); no grace period specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The de minimis exemption (Section 321) for mail shipments is indefinitely suspended, and a new postal informal entry process is implemented, requiring formal entry filings for all imported mail shipments regardless of value.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) importing small quantities of samples, APIs, or finished drugs via mail.
What you must do
Update import procedures to ensure all mail shipments are accompanied by proper entry documentation (e.g., CBP Form 3461, bond, commercial invoice) and comply with FDA/DEA requirements.
Deadline
Effective immediately upon publication (June 24, 2026); no grace period specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness